108 related articles for article (PubMed ID: 23042614)
1. Personalized medicine benefits patients in early trials: matching targeted therapies with gene mutations is associated with better outcomes, even in phase 1 studies.
Printz C
Cancer; 2012 Oct; 118(20):4911-2. PubMed ID: 23042614
[No Abstract] [Full Text] [Related]
2. Personalized oncology: genomic screening in phase 1.
Tuxen IV; Jønson L; Santoni-Rugiu E; Hasselby JP; Nielsen FC; Lassen U
APMIS; 2014 Aug; 122(8):723-33. PubMed ID: 25046202
[TBL] [Abstract][Full Text] [Related]
3. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
4. Genomics, personalized medicine and cancer practice.
Dancey J
Clin Biochem; 2012 Apr; 45(6):379-81. PubMed ID: 22424082
[No Abstract] [Full Text] [Related]
5. Impact of genomics on personalized cancer medicine.
Arteaga CL; Baselga J
Clin Cancer Res; 2012 Feb; 18(3):612-8. PubMed ID: 22298893
[TBL] [Abstract][Full Text] [Related]
6. Hotspot oncomutations: implications for personalized cancer treatment.
Myers MB; Wang Y; McKim KL; Parsons BL
Expert Rev Mol Diagn; 2012 Jul; 12(6):603-20. PubMed ID: 22845481
[TBL] [Abstract][Full Text] [Related]
7. [Personalized therapy].
Hallek M; Wolf J
Internist (Berl); 2013 Feb; 54(2):145-6. PubMed ID: 23371256
[No Abstract] [Full Text] [Related]
8. The genetic basis for cancer treatment decisions.
Dancey JE; Bedard PL; Onetto N; Hudson TJ
Cell; 2012 Feb; 148(3):409-20. PubMed ID: 22304912
[TBL] [Abstract][Full Text] [Related]
9. Personalized medicine: the medicine of tomorrow. Foreword.
Tremblay-Servier M
Metabolism; 2013 Jan; 62 Suppl 1():S1. PubMed ID: 23018144
[No Abstract] [Full Text] [Related]
10. Biospecimen banking: the pathway to personalized medicine for patients with cancer.
Scolyer RA; Thompson JF
J Surg Oncol; 2013 Jun; 107(7):681-2. PubMed ID: 23280671
[No Abstract] [Full Text] [Related]
11. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
[TBL] [Abstract][Full Text] [Related]
12. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
[TBL] [Abstract][Full Text] [Related]
13. Early phase clinical trials in pediatric hematology and oncology.
Corbacioglu S
Klin Padiatr; 2012 Apr; 224(3):197-200. PubMed ID: 22511313
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
15. Biology-driven phase II trials: what is the optimal model for molecular selection?
Andre F; Delaloge S; Soria JC
J Clin Oncol; 2011 Apr; 29(10):1236-8. PubMed ID: 21343554
[No Abstract] [Full Text] [Related]
16. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
Ludwig WD
Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
[TBL] [Abstract][Full Text] [Related]
17. [Personalized therapeutic targeting by exome analysis].
Lamy A; Angot E; Sabourin JC
Ann Pathol; 2012 Nov; 32(5 Suppl):S44-5. PubMed ID: 23127937
[No Abstract] [Full Text] [Related]
18. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic.
Stricker T; Catenacci DV; Seiwert TY
Semin Oncol; 2011 Apr; 38(2):173-85. PubMed ID: 21421108
[TBL] [Abstract][Full Text] [Related]
20. [Personalized medicine and molecular targets of drugs].
Nishiyama M
Nihon Rinsho; 2010 Oct; 68(10):1917-22. PubMed ID: 20954340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
